AbbVie Inc. (NYSE: ABBV) and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a clinical-stage immunotherapy company, have announced a strategic partnership aimed at developing OSE-230, a monoclonal antibody designed to address chronic and severe inflammation. Currently in the pre-clinical development stage, OSE-230 represents a promising advancement in the treatment landscape.
OSE-230 is a pioneering monoclonal antibody crafted to activate ChemR23, a G-Protein Coupled Receptor (GPCR) target. This activation holds the potential to offer a fresh mechanism for resolving chronic inflammation by modulating the functions of both macrophages and neutrophils.
Jonathon Sedgwick, Ph.D., Senior Vice President and Global Head of Discovery Research at AbbVie, expressed their commitment to expanding the immunology portfolio to enhance patient care globally. Sedgwick stated, “By leveraging our expertise in immunology drug development, we look forward to advancing OSE-230, which offers a novel mechanism-of-action to treat chronic inflammation.”
Nicolas Poirier, CEO of OSE Immunotherapeutics, emphasized the significance of this collaboration with AbbVie, a renowned leader in developing and commercializing innovative medicines. Poirier acknowledged the milestone reached and attributed it to the dedication and hard work of all employees.
Under the agreement’s terms, AbbVie gains an exclusive global license for the development, manufacturing, and commercialization of OSE-230. OSE Immunotherapeutics stands to receive a substantial upfront payment of $48 million and could potentially earn up to an additional $665 million in milestone payments linked to clinical development, regulatory approvals, and commercialization. Furthermore, OSE Immunotherapeutics may also be entitled to receive tiered royalties based on global net sales of OSE-230.
The completion of the transaction is contingent upon meeting customary closing conditions, including the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.
AbbVie is dedicated to discovering and delivering innovative medicines and solutions to address pressing health challenges today and in the future. The company focuses on several therapeutic areas, including immunology, oncology, neuroscience, and eye care, along with products and services in the Allergan Aesthetics portfolio. For more information, visit www.abbvie.com or follow @abbvie on social media platforms.
OSE Immunotherapeutics is a biotech company committed to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I). The company’s diverse pipeline includes promising candidates such as Tedopi®, OSE-279, OSE-127 (lusvertikimab), FR-104/VEL-101, BI 765063, BI 770371, and OSE-230. These initiatives align with OSE Immunotherapeutics’ goal of delivering next-generation first-in-class immunotherapies.
